natgillin/translations-raw huggingface dataset:
the autoactivation step is performed after purification of the autoactivating proelastase protein; or 
(a) autoaktivacijski korak izveden poslije pročišćavanja autoaktivacijskog proteina proelastaze; ili
The integrated circuit according to claim 1 wherein Localized Virtual Resource Blocks (LVRBs), which are mapped to PRBs, are allocated to the terminal by units of RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
Cosmetic method for improving and/or increasing and/or stimulating and/or promoting and/or inducing the pigmentation of hair and/or hairs, comprising the administration of a composition comprising an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species. 
Kozmetička metoda za poboljšanje i/ili povećanje i/ili stimulaciju iili promicanje 1/ili poticanje pigmentacije kose iili vlasi, koja obuhvaća davanje pripravka koji sadrži ekstrakt Allium vrsta, ekstrakt Citrus vrsta, ekstrakt Paullinia vrsta i ekstrakt Theobroma vrste.
Aflibercept for use in treating a patient according to any one of claims 1 to 7 and 9 to 16, wherein the folinic acid is administered intravenously immediately after aflibercept administration over a period of 2 hours. 
Aflibercept za uporabu u liječenju pacijenta prema bilo kojem od patentnih zahtjeva 1 do 7 19 do 16, naznačen time što se folinska kiselina daje intravenozno odmah nakon primjene aflibercepta tijekom perioda od 2 sata.
The nucleic acid of any one of the preceding claims, further comprising a non-human regulatory element and a leader sequence operably linked to the nucleotide sequence. 
Miš iz bilo kojeg zahtjeva 9. – 11. pri čemu je nukleotidni slijed operabilno povezan s endogenim regulatornim elementima miša.
harvesting said peptide analog. Method according to claim 13, comprising ring closure by chemical or enzymatic means, preferably by enzymatic means. 
Postupak prema zahtjevu 13, koji sadrži zatvaranje prstena kemijskim ili enzimatskim sredstvima, poželjno enzimatskim sredstvima.
The process for preparing a vaccine composition as claimed in claim 17, wherein the conjugate obtained in a) is combined with diphtheria toxoid, tetanus toxoid, and acellular Bordetella pertussis antigens toxoid and filamentous hemagglutinin. 
Postupak za pripravu pripravka cjepiva prema zahtjevu 12 ili 13, naznačen time da se konjugat dobiven u koraku b) kombinira s toksoidom difterije, toksoidom tetanusa, 1 2 acelularna antigena Bordetella pertussis, koji su toksoid i filamentozni hemaglutinin.
[Paragraph 7] The modified IgG4 Fc fragment of paragraph 1, wherein the hinge region was mutated by the deletion of 1 to 3 continuous or discontinuous amino acid(s) comprising a Cys residue at the 8th position. 
Modificirani IgG4 Fc fragment prema zahtjevu 1, naznačeno time da je zglobna Tegija mutirana putem brisanja od 1 do 3 uzastopne/ih ili neuzastopne/ih aminokiselina sadržeći Cis ostatak na osmom položaju.
Use of a polymer fiber according to any of claims 1-4 or 7 as an additive, for example in concrete, mortar, plaster, cement or refractory material. 
Upotreba polimernog vlakna u skladu s patentnim zahtjevom 1, naznačena time što ga se upotrebljava za poboljšavanje vatrostalnosti betona, žbuke, gipsa, cementa ili vatrostalnog materijala.
The compound for use according to claim 7, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage. 
Spoj za upotrebu prema zahtjevu 6, pri čemu modificirana internukleozidna veza je fosforotioatna internukleozidna veza.
drying the obtained precipitate at a temperature ranging from room temperature to 40° C. under a pressure ranging from ambient pressure to under vacuum, for a duration of time ranging from 5 minutes to 1 day. The solid precipitate can be washed by the use of apolar solvent C3-C7 linear or cyclic or aromatic alkyl. 
sušenja dobivenog taloga na temperaturi u rasponu od sobne temperature do 40 *C pod tlakom koji se kreće između tlaka okoliša i vakuuma, u trajanju u rasponu od 5 minuta do 1 dan, gdje se talog prije sušenja može isprati nepolarnim otapalom.
A bicycloester derivative represented by the following general formula (1): wherein R1 is a substituted or unsubstituted C1 to C6 alkyl group, substituted or unsubstituted C3 to C6 cycloalkyl group, tetrahydropyranyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted arylethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring, or substituted or unsubstituted aliphatic heterocyclic ring; X is CH2, CHF, CF2, CHOH, S, or O; and n is 1, 2, or 3, or a pharmaceutically acceptable salt thereof. 
Derivat bicikloestera, naznačen time što ga prikazuje sljedeća opća formula (1): [image] u kojoj R1 je supstituirana ili nesupstituirana C1 do C6 alkilna skupina, supstituirana ili nesupstituirana C3 do C6 cikloalkilna skupina, tetrahidropiranilna skupina, supstituirana ili nesupstituirana arilmetilna skupina, supstituirana ili nesupstituirana ariletilna skupina, supstituirana ili nesupstituirana aromatska ugljikovodična skupina, supstituirani ili nesupstituirani aromatski heterociklički prsten ili supstituirani ili nesupstituirani alifatski heterociklički prsten;
at least one substitution selected from the group consisting of: 
(A) najmanje jedne zamjene, koju se bira iz skupine koju čine:
A pharmaceutical composition comprising rFSH including a2,3-sialylation and a2,6-sialylation wherein 60% or more of the total sialylation is a2,3-sialylation and from 5 to 40% of the total sialylation is a2,6-sialylation; and having a sialic acid content [expressed in terms of a ratio of moles of sialic acid to moles of protein] of 10 mol/mol to 16 mol/mol. 
Farmaceutski pripravak koji sadrži rFSH uključujući 02,3-sialilaciju i 02,6-sialilaciju gdje 60% ili više od ukupne sialilacije je 02,3-sialilacija i od 5 do 40% od ukupne sialilacije je 02,6-sialilacija; te ima sadržaj sijalinske kiseline [izražen terminom omjera molova sijalinske kiseline prema molovima proteina] od 10 mol/mol do 16 mol/mol.
The inner retainer 72 associated with each ball spline nut 42, 43 is telescopically and slidably received at least in part within the central cylinder 62. 
Unutrašnji držač (72) povezan s kuglasto-klinastim maticama (42), (43) se može klizno teleskopski uvući barem djelomično unutar središnjeg cilindra (62).
A capsule according to clause 39, wherein the height of the further ridge is larger than the height of the at least one projection. 
Kapsula (2) prema zahtjevu 21, naznačena time, da je visina dodatnog grebena (40) veća od visine grebena (28.i).
demultiplexing the bit interleaved Layer 1 signaling data into cell words; 
demultipleksiranje umetnutih PLP podataka u stanične riječi;
The rodent of any preceding claim, wherein the rodent is a rat or mouse. 
Glodavac u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je glodavac štakor ili miš.
express one or more genes at a detectably higher level than an equivalent number of bone marrow derived mesenchymal stem cells, wherein said one or more genes comprise one or more of BMP4, BMP6, CD36, CDH11, COL14A1, COL15A1, COL1A1, COL3A1, COLSA1, CSF2, CTSK, FGF2, FGFR1, FLT1, ITGA1, MINPP1, MMP9, MSX1, PDGFA,SERPINH1, TGFB3 and TGFBR1, wherein said OPACs and said mesenchymal stem cells have undergone an equivalent number of passages; or express one or more genes at a detectably higher level than an equivalent number of fibroblast cells, wherein said one or more genes comprise one or more of BMP4, BMP6, CDH11, COL14A1, COL15A1, COL1A1, COL3A1, COLSA1, FLT1, IGF1R, ITGA1, MINPP1, PDGFA, SERPINH1, SMAD3, TGFB1, TGFB2, TGFB3, TGFBR1, TNF, TUFT1, VCAM1 and VEGFA, and wherein said fibroblast cells have undergone an equivalent number of passages. 
Izolirani OPAC, namijenjeni upotrebi u skladu s patentnim zahtjevom 1, naznačeni time što navedeni OPAC: eksprimiraju jedan ili više gena na mjerljivo višoj razini nego odgovarajući broj mezenhimnih matičnih stanica iz koštane srži, gdje navedeni jedan ili više gena uključuju jedan ili više od BMP4, BMP6, CD36, CDH11, COLI4AIJ, COL1S5A1, COLIA1l, COL3A1, COLSA1, CSF2, CTSK, FGF2, FGFRI, FLTI, ITGA1, MINPP1, MMP9, MSCI, PDGFA, SERPINH1, TGFB3 i TGFBRI1, gdje su navedeni OPAC i navedene mezenhimne matične stanice prošli ekvivalentan broj pasaža; ili eksprimiraju jedan ili više gena na mjerljivo višoj razini nego odgovarajući broj fibroblasta, gdje navedeni jedan ili više gena uključuju jedan ili više od BMP4, BMP6, CDH11, COLI4A1, COLISA1, COLIA1, COL3A1, COLSAI, FLTI, IGFIR, ITGA1, MINPPI, PDGFA, SERPINHI1, SMAD3, TGFB1, TGFB2, TGFB3, TGFBRI, TNF, TUFT1, VCAMI i VEGFA, te gdje su navedeni OPAC 1 navedeni fibroblasti prošli ekvivalentan broj pasaža.
In certain embodiments, the BC loop comprises an amino acid sequence selected from SEQ ID NOs: 7, 11-21, 23-31, 34, and 36-38, the DE loop comprises an amino acid sequence selected from SEQ ID NOs: 39 and 42, and the FG loop comprises an amino acid sequence selected from SEQ ID NOs: 46, 50-62, 64-72, 75-77, and 79. 
(x) - alanin na položaju 10 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine koju čine C, G,L, M, Si T; ili (xi) = asparagin na položaju 11 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine kojučine A, C,F,H,P,Q,R, Si Y.
8.The telomerase inhibitor for the use according to claim 7, wherein the at least one symptom alleviated comprises enlarged spleen, splenic pain, anemia, bone pain, fatigue, fever, night sweats, weight loss, weakness, fainting, nosebleeds, bruising, bleeding from the mouth or gums, bloody stool, or stroke. 
Inhibitor telomeraze za uporabu u skladu s patentnim zahtjevom 1, naznačen time što najmanje jedan ublaženi simptom sadrži uvećanu slezenu i bol u slezeni, ranu sitost, anemiju, bol u kostima, umor, groznicu, noćno znojenje, gubitak u tjelesnoj težini, slabost, nesvjesticu, krvarenje iz nosa, pojavu modrica, krvarenje iz usta ili desni, krvavu stolicu ili moždani udar.
The process of any one of claims 10, 11, 12, and 13, wherein the oil used in the extraction treatment is selected from the group consisting of vegetable oils, animal oils, mineral oils, and combinations thereof. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što se ulje upotrijebljeno u obradi ekstrahiranjem bira iz skupine koju čine biljna ulja, životinjska ulja, mineralna ulja, te njihove kombinacije.
is hydrogen or up to three substituents independently selected from halogen, C(1-4)alkyl, C(1-4)alkoxy, trifluoromethoxy, difluoromethoxy, trifluoromethyl, cyano, optionally substituted phenyl and optionally substituted 5 or 6 membered heteroaryl rings; is hydrogen or up to three substituents independently selected from halogen, C(1-4)alkyl, C(1-4)alkoxy, trifluoromethoxy, difluoromethoxy, trifluoromethyl and cyano; R3, R3', R4 and R4' are each independently selected from hydrogen, halogen and methyl; 
R, je vodik 1li do tri supstituenta, koje se neovisno bira između halogena, C(14,alkila, C(i.qalkoksi, trifluormetoksi, difluormetoksi, trifluormetila, cijano i izborno supstituiranih fenilnih ili izborno supstituiranih 5- ili 6-eročlanih heteroarilnih prstena; R, je vodik ili do tri supstituenta, koje se neovisno bira između halogena, C(1.4alkila, C(a.galkoksi, trifluormetoksi, difluormetoksi, trifluormetila i cijano; svakog od R,, Rs, Ry i Ry: se neovisno bira između vodika, halogena i metila;
A dosage unit of asenapine maleate, suitable for the treatment of mental disorders such as psychosis, bipolar disorders and schizophrenia may contain from about 0.005 to 500 mg of the active ingredient. 
Jedinica za doziranje asenapin maleata, pogodna za liječenje mentalnih poremećaja kao što su psihoze, bipolarni poremećaji i shizofrenija mogu sadržavati od oko 0,005 do 500 mg aktivnog sastojka.
A pharmaceutical composition comprising a compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent. 
Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem zahtjevu 1 do 10, u slobodnom bazičnom obliku ili u obliku farmaceutski prihvatljive dodatne kiselinske soli, s pripojenim farmaceutskim nosačem ili razrjeđivačem.
A porcelain pot according to Claim 1, characterized in that the raw materials of said glaze formula consists only of 0,2 Na2O, 0,1 K2O, 0,4 CaO, 0,3 MgO, 0,1 Al2O3 and 4,6 SiO2 according to Seger formula. 
Porculanski lonac sukladno patentnom zahtjevu 1, naznačen time što sirovine navedene formule glaziranja sarže samo 0,2 Na20, 0,1 K20, 0,4 Ca0, 0,3 MgO, 0,1 AbO3 1 4,6 SiO, u skladu sa Zegerovom formulom.
Particular preference is given to the compounds of the formula I in which R3, R4 
Spojevi formule I u skladu s patentnim zahtjevom 1, gdje X je veza;
is a hydrogen atom, a halogen atom or a lower alkyl group optionally having substituent(s); 
R' je atom vodika, atom halogena ili alkilna skupina koja ima broj ugljika od 1 do 6 opcijski sa supstituentima;
an effective amount of buffer to maintain the pH in a range of 4.5 to 5.5; 
učinkovitu količinu pufera da se pH održi u opsegu 4,5 do 5,5;
The term "Chloro Acetamides" shall mean herein the compounds as such as well as a) their salts, e.g. salts of alkaline or earth alkaline metals or ammonium or organoammonium salts, for instance, sodium, potassium, ammonium, isopropyl ammonium etc. or b) their respective isomers, e.g. stereo isomers such as the respective enantiomers. 
Termin "kloroacetamidi" ovdje označavaju spojeve kao takve kao i a) njihove soli, npr. soli alkalnih ili zemnoalkalnih metala, amonijeve ili organoamonijeve soli, na primjer, natrijeve, kalijeve, amonijeve soli, izopropil amonijeve soli, itd., ili b) njihove odgovarajuće izomere, npr. stereoizomere kao što su odgovarajući enantiomeri.
System for covering of glass surfaces with a composition based on tin tetrachloride anhydrous according to the claim 8 wherein the system includes a mechanism for temperature control (16) with a thermostat which it registers at any time the temperature inside the tunnel (1) and that it is programmed by a temperature of control below which the mechanism of control interrupts automatically the supply of electricity to the dosing pump (7), interrupting the pulverization of mixture of composition based on tin tetrachloride anhydrous and air to the interior of the tunnel (1). 
Sistem za prekrivanje staklenih površina sa kompozicijom baziranom na bezvodnom kositar tetrakloridu prema patentnom zahtjevu 8 pri čemu sistem uključuje mehanizam (16) za kontrolu temperature sa termostatom koji registrira u bilo koje vrijeme temperaturu unutar tunela (1) 1 koji je programiran pomoću temperature kontrole ispod koje mehanizam kontrole automatski prekida opskrbu električnom energijom pumpe (7) za doziranje, prekidajući raspršivanje smjese kompozicije bazirane na bezvodnom kositar tetrakloridu i zraka u unutrašnjosti tunela (1).
22, a L-CDR1 sequence which is 64% or more identical to the L-CDR1 sequence shown in SEQ ID NO. 
22, (iv) slijed L-CDRI, koji je 64% ili više istovjetan slijedu L-CDRI prikazanom u SEQ ID NO.
Sugar replacement composition according to one of the preceding claims, further comprising SiO2 in an amount effective to prevent caking of said sugar replacement composition. 
Sastavina koja zamjenjuje šećer iz jednog od prethodnih patentnih zahtjeva, koja nadalje sadržava SiO, u količini dovoljnoj da spriječi zgrudnjavanje rečene sastavine koja zamjenjuje šećer.
Use or pharmaceutical composition for use according to claim 7, wherein the ionizing radiations are of about 50 KeV to about 12 000 KeV. 
Uporaba farmaceutskog sastava za uporabu u skladu s patentnim zahtjevom 7, pri čemu su ionizirajuća zračenja oko 50 KeV do oko 12000 KevV.
Adventitial fat was removed, and aortas were opened longitudinally; immersed in Red Oil solution for overnight, washed in propylenglycol and fixed onto a flat surface. 
Adventicijska mast je odstranjena i aorte su otvorene uzdužno, uronjene u Red Oil otopinu preko noći, isprane u propilen-glikolu i učvršćene na ravnu površinu.
storing the EDR data on a memory of an onboard hardware platform. The method of claim 15, further comprising: converting the EDR data into a format readable by an Internet browser software; and 
Postupak sukladno zahtjevu 15, naznačen time, da nadalje obuhvaća: konvertiranje EDR podataka u format čitljiv putem internetskog preglednika; i prijenos konvertiranih EDR podataka do udaljenog računala.
The compound of Claim 1, where R2 is -OH and R3 is -CH3. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R2 -OH i R3 je -CH3.
an actuator to control movement of the arm relative to the anchoring portion, wherein the actuator includes a cord or rope or chain, which is connected to the arm to allow the actuator to rotate around a rotation axis. 
Sustav u skladu sa patentnim zahtjevom 10, koji sadrži sredstvo za aktiviranje za kontrolu pokreta ručke (26) u odnosu na dio (20) za učvršćivanje, gdje sredstvo za aktiviranje uključuje uže ili konopac (36) ili lanac, koji je povezan sa ručkom (26) kako bi mu se omogućilo da se okreće oko osi rotacije.
a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, a cell according to claim 7, or an activated cytotoxic T lymphocyte according to claim 10, in solution or in lyophilized form; 
posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, nukleinskom kiselinom ili vektorom ekspresije u skladu s patentnim zahtjevom 4, stanicom u skladu s patentnim zahtjevom 6 ili 7 ili aktiviranim citotoksičnim T limfocitom u skladu s patentnim zahtjevom 10, u otopini ili u liofiliziranom obliku; te
The wetted mixture was dried in a fluid-bed dryer using an inlet air temperature of 70 °C. The obtained dry granulate was sieved using a sieving machine. 
Vlažna smjesa osušena je u sušilu fluidnog ležišta koristeći ulaznu struju zraka temperature 70 *C. Dobiveni suhi granulat prosijan je koristeći aparat za prosijavanje.
The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R4 is morpholin-4-yl or 
KI \ NM N=< Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time što
Process according to claim 5, which further comprises adding water to the reaction mixture, after conclusion of the reaction, to precipitate atorvastatin tert.-butyl ester (II). 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se dodatno sastoji u dodavanju vode u reakcijsku smjesu, nakon dovršenja reakcije, kako bi se istaložilo tert-butilni ester atorvastatina (11).
The battery exchange station according to 8, wherein the second conveyor is configured to make contact with the back wheel of the vehicle, after a battery service process is completed at the second substation, and push the vehicle until a third conveyor in the series of conveyors which makes contact with the front wheel of the vehicle to push the vehicle to a third substation of the plurality of substations. 
primanje vozila (102) preko sustava kliznih vrata (700) tako da barem jedan kotač vozila leži na pokretnom sustavu; i pomicanje vrata u prvom smjeru uz omogućavanje pokretnom sustavu da klizi u drugom smjeru koji je suprotan prvom smjeru uz istodobno držanje barem jednog kotača, pri čemu se klizanje vrata (704) i klizanje pokretnog sustava (706) događa barem djelomično istovremeno.
A substituted morpholine or thiomorpholine derivative of the general formula I wherein q is 0 or 1; 
Supstituirani derivat morfolina ili tiomorfolina opće formule I [image] naznačen time što q je 0 ili 1;
Reaction mixture is quenched with water, concentrated under vacuum and aqueous layer is extracted with ethyl acetate (3x25 mL). 
Reakcijsku smjesu ugasi se vodom, te koncentrira u vakuumu, a vodeni sloj ekstrahira etilacetatom (3 x 25 ml).
The method as claimed in claim 1, wherein the cotton is selected from the group consisting of natural cotton, surgical cotton, clinical grade cotton, commercial cotton, spun cotton, water washed cotton, acid or base washed cotton, autoclaved cotton, buffer treated cotton having a pH ranging from about 1 to about 14, salt solution treated cotton, organic solvent treated cotton, pressed cotton and processed cotton. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se pamuk bira iz skupine koju čine prirodni pamuk, kirurški pamuk, pamuk kliničke kvalitete, komercijalni pamuk, predeni pamuk, pamuk pran vodom, pamuk pran kiselinom ili bazom, autoklavirani pamuk, puferirani pamuk s pH u rasponu od otprilike 1 do otprilike 14, pamuk obrađen otopinom soli, pamuk obrađen organskim otapalom, tiješteni pamuk i prerađeni pamuk.
reacting a compound of Formula A in an organic solvent with base and (S)-propylene glycol, optionally adding seeds of the (S)-PG compound la, to yield the compound of Formula la. 
reakcije spoja sa Formulom A u organskom otapalu sa bazom i (S)-propilen glikolom, te proizvoljno dodavanje zametaka (S)-PG spoja Ia, da se dobije spoj sa Formulom Ia.
Triggering the transformation before the curing is undesired since the volume compensating effect will be less or lost depending on how much is transformed before curing is initiated. 
Poticanje transformacije prije očvršćivanja je nepoželjno jer će učinak koji kopmenzira volumen biti manji ili izgubljen, ovisno do kolike je transformacije došlo prije početka očvršćivanja.
In one embodiment, the other therapeutic agent is selected from inotropes, beta adrenergic receptor blockers, HMG-Co-A reductase inhibitors, angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) Inhibitors, calcium channel blockers (CCB), endothelin antagonists, renin inhibitors, diuretics, ApoA-I mimics, anti-diabetic agents, obesity-reducing agents, aldosterone receptor blockers, endothelin receptor blockers, aldosterone synthase inhibitors (ASI), a CETP inhibitor, anti-coagulants, relaxin, BNP (nesiritide) and a NEP inhibitor. 
Kombinacija prema zahtjevu 18, naznačena time, da je ko-agens odabran od sljedećih: inotropni spojevi, beta blokatori adrenergijskih receptora, inhibitori reduktaze HMG-Co-A, antagonisti receptora angiotenzina II, inhibitori enzima pretvorbe angiotenzina (ACE), blokatori kanala kalcija (CCB), antagonisti endotelina, inhibitori renina, diuretici, ApoA-I-mimetici, antidijabetska sredstva, sredstva za smanjenje pretilosti, blokatori receptora aldosterona, blokatori receptora endotelina, inhibitori sinteze aldosterona (ASI), CEPT-inhibitor, antikoagulanti, relaksin, BNP (nesiritid) i/ili NEP-inhibitor.
A method of inhibiting the growth of fungi, or killing fungi, said method comprising contacting said fungi with the compound of claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, za upotrebu u prevenciji, stabilizaciji ili inhibiciji rasta gljivica ili istrebljenju gljivica.
A head according to claim 4, characterized by comprising a movable structure carrying said second pressing roller, said first actuation and guide means, and said actuation means; said hinge being interposed between said frame and said movable structure. A head according to claim. 
Glava u skladu s bilo kojim od patentnih zahtjeva 4 do 7, naznačena time, da obuhvaća pokretnu strukturu koja nosi navedeni drugi valjak za prešanje, navedena prva sredstva za aktiviranje 1 vođenje 1 navedena sredstva za aktiviranje; pri čemu je navedeni zglob umetnut između navedenog okvira i navedene pokretne strukture.
A composition comprising an ether solvent that has low miscibility with water and at least ten moles of a boronic ester compound of formula (I): wherein: 
Kompozicija koja sadrži etersko otapalo koji ima nisku mješavost sa vodom i najmanje deset mola spoja estera organoborne kiseline formule (7): R2 R'